Benefits
Documented blood NAD+ elevation
Multiple clinical trials show NR supplementation raises blood NAD+ levels 40-50% at standard doses within 2-4 weeks. The biomarker effect is well-established and reproducible — addresses the age-related NAD+ decline that's been hypothesized to contribute to multiple aging-related conditions.
Mitochondrial function support (preliminary)
Cellular and animal studies show NR supports mitochondrial biogenesis, function, and resistance to oxidative damage through NAD+-dependent sirtuin and PARP enzyme activation. Human evidence for functional mitochondrial improvements is emerging but less robust than the biomarker NAD+ elevation.
Cardiovascular biomarkers in older adults
A single small crossover trial (Martens 2018) suggested a possible reduction in blood pressure and arterial stiffness in participants with elevated baseline BP, but the effect did not reach statistical significance. No cardiovascular outcome benefit has been demonstrated; outcome trials are needed.
Possible cognitive aging support
Animal studies suggest NR supports neuronal function and may protect against cognitive aging. Human clinical evidence for cognitive function improvement is preliminary; not yet validated as a cognitive enhancer in healthy adults or as a treatment for mild cognitive impairment.
Sirtuin and PARP enzyme support
NAD+ is required for sirtuin enzymes (involved in longevity pathways) and PARP enzymes (DNA repair). NR supplementation supports these enzyme activities at the biochemical level. Mechanism aligns with longevity-research positioning, though human longevity outcomes remain unproven.
Honest counter-evidence on clinical benefits
While NR reliably elevates blood NAD+, translating this to clear clinical benefits in healthy adults has been more elusive. Many specific health benefit claims rest on mechanism rather than well-validated clinical trials. The 'longevity' positioning is partially speculative based on mouse models.
Mechanism of action
Nucleoside-transporter uptake and NRK phosphorylation
NR enters cells via nucleoside transporters and is phosphorylated by NR kinases (NRK1/2) to form NMN, which is then adenylylated to NAD+. This pathway bypasses the rate-limiting NAMPT step that limits nicotinamide (niacinamide) conversion — making NR one of the most efficient oral NAD+ precursors.
Sirtuin activation (SIRT1–7)
Elevated NAD+ activates all seven sirtuin deacylases simultaneously. SIRT1 and SIRT3 are particularly important — SIRT1 drives mitochondrial biogenesis via PGC-1α deacetylation, while SIRT3 protects mitochondria from oxidative damage and regulates metabolic enzymes.
PARP-1 and DNA repair
PARP-1 consumes NAD+ during DNA strand break repair. Chronically elevated PARP-1 activity (from accumulating DNA damage with age) depletes cellular NAD+, creating a vicious cycle. NR restores NAD+ substrate availability for both PARP-1 and sirtuins — two competing yet complementary longevity mechanisms.
Clinical trials
First-in-human dose-escalation study of nicotinamide riboside (Niagen®) at 100, 300, and 1,000 mg in an acute single-dose escalation in 12 healthy adults. Outcomes: whole-blood NAD+, NAD+ metabolome. (Nat Commun)
12 healthy adults. 8-week dose-escalation.
All doses dose-dependently elevated whole-blood NAD+, with larger increases at higher doses. Foundational human PK trial confirming oral NR raises NAD+ levels. Critical caveat: NAD+ elevation is a biomarker — does not directly establish clinical benefits. The translation from elevated NAD+ to meaningful clinical outcomes (longevity, healthspan) remains an active research question with limited definitive human data.
Randomized, double-blind, crossover trial of NR (1,000 mg/day) vs placebo in 30 adults aged 55-79 with elevated SBP for 6 weeks each. (Nat Commun)
30 adults aged 55-79 with elevated BP.
NR raised NAD+ ~60% and was well tolerated. A reduction in aortic pulse wave velocity and systolic blood pressure was seen only as a non-significant trend (suggestive in the subgroup with elevated baseline BP); the trial was not powered for these outcomes and a cardiovascular benefit was not statistically demonstrated.
GRAS-affirmed safety trial examining NR supplementation (250-2,000 mg/day) in healthy adults for 8 weeks. (Sci Rep)
Healthy adults. Safety study.
No serious adverse effects at any dose up to 2,000 mg/day. No changes in liver enzymes, kidney function, lipids. Generally well-tolerated. Established NR safety profile for supplemental use.